KR20140116103A - 치료 방법 - Google Patents
치료 방법 Download PDFInfo
- Publication number
- KR20140116103A KR20140116103A KR1020147019564A KR20147019564A KR20140116103A KR 20140116103 A KR20140116103 A KR 20140116103A KR 1020147019564 A KR1020147019564 A KR 1020147019564A KR 20147019564 A KR20147019564 A KR 20147019564A KR 20140116103 A KR20140116103 A KR 20140116103A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- nrp2
- mice
- hippocampus
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 51
- 238000011282 treatment Methods 0.000 title claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 89
- 210000001320 hippocampus Anatomy 0.000 claims abstract description 79
- 201000010099 disease Diseases 0.000 claims abstract description 55
- 210000001178 neural stem cell Anatomy 0.000 claims abstract description 48
- 241000124008 Mammalia Species 0.000 claims abstract description 33
- 230000004694 hippocampus damage Effects 0.000 claims abstract description 7
- 102000004899 14-3-3 Proteins Human genes 0.000 claims description 167
- 108700020469 14-3-3 Proteins 0.000 claims description 158
- 101150094625 14-3-3zeta gene Proteins 0.000 claims description 151
- 210000004027 cell Anatomy 0.000 claims description 121
- 101150106321 Nrp2 gene Proteins 0.000 claims description 55
- 201000000980 schizophrenia Diseases 0.000 claims description 50
- 210000004556 brain Anatomy 0.000 claims description 33
- 208000035475 disorder Diseases 0.000 claims description 33
- 210000000130 stem cell Anatomy 0.000 claims description 15
- 102100022273 Disrupted in schizophrenia 1 protein Human genes 0.000 claims description 14
- 101000902072 Homo sapiens Disrupted in schizophrenia 1 protein Proteins 0.000 claims description 14
- 208000028017 Psychotic disease Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 208000020925 Bipolar disease Diseases 0.000 claims description 9
- 210000004268 dentin Anatomy 0.000 claims description 7
- 210000003780 hair follicle Anatomy 0.000 claims description 7
- 210000004504 adult stem cell Anatomy 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 206010012218 Delirium Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 206010019196 Head injury Diseases 0.000 claims description 4
- 208000028810 Shared psychotic disease Diseases 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000000933 neural crest Anatomy 0.000 claims description 4
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 3
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 3
- 208000029650 alcohol withdrawal Diseases 0.000 claims description 3
- 201000002545 drug psychosis Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 208000027534 Emotional disease Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 208000022610 schizoaffective disease Diseases 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 206010021079 Hypopnoea Diseases 0.000 claims 1
- 208000020186 Schizophreniform disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 107
- 238000012360 testing method Methods 0.000 description 57
- 241000699666 Mus <mouse, genus> Species 0.000 description 53
- 210000002569 neuron Anatomy 0.000 description 48
- 239000010410 layer Substances 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 39
- 230000000971 hippocampal effect Effects 0.000 description 38
- 208000024891 symptom Diseases 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 21
- 210000002763 pyramidal cell Anatomy 0.000 description 19
- 239000000835 fiber Substances 0.000 description 16
- 108010029485 Protein Isoforms Proteins 0.000 description 14
- 102000001708 Protein Isoforms Human genes 0.000 description 14
- 210000001176 projection neuron Anatomy 0.000 description 14
- 210000001947 dentate gyrus Anatomy 0.000 description 13
- 230000001537 neural effect Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000006977 prepulse inhibition Effects 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 11
- 230000007547 defect Effects 0.000 description 11
- 210000001787 dendrite Anatomy 0.000 description 11
- 210000001353 entorhinal cortex Anatomy 0.000 description 11
- 210000004295 hippocampal neuron Anatomy 0.000 description 11
- 230000015654 memory Effects 0.000 description 11
- 208000004547 Hallucinations Diseases 0.000 description 10
- 230000002159 abnormal effect Effects 0.000 description 10
- 206010012239 Delusion Diseases 0.000 description 8
- 210000003050 axon Anatomy 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000013016 learning Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- 101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 7
- 101150051337 NRP1 gene Proteins 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 231100000868 delusion Toxicity 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000003710 cerebral cortex Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000000946 synaptic effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 206010052804 Drug tolerance Diseases 0.000 description 5
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 5
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 5
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000026781 habituation Effects 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 230000017511 neuron migration Effects 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000013290 Sagittaria latifolia Nutrition 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 210000005056 cell body Anatomy 0.000 description 4
- 235000015246 common arrowhead Nutrition 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 230000036278 prepulse Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 230000031836 visual learning Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 230000007278 cognition impairment Effects 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 210000003981 ectoderm Anatomy 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000002475 olfactory pathway Anatomy 0.000 description 3
- 238000012346 open field test Methods 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 210000000063 presynaptic terminal Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000698 schizophrenic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102100027153 Ankyrin repeat and sterile alpha motif domain-containing protein 1B Human genes 0.000 description 2
- 101710149294 Ankyrin repeat and sterile alpha motif domain-containing protein 1B Proteins 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101001064282 Homo sapiens Platelet-activating factor acetylhydrolase IB subunit beta Proteins 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 101150006989 NDEL1 gene Proteins 0.000 description 2
- 102100030655 Platelet-activating factor acetylhydrolase IB subunit beta Human genes 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004874 Synaptophysin Human genes 0.000 description 2
- 108090001076 Synaptophysin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000006400 anxiety behaviour Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000028600 axonogenesis Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000006736 behavioral deficit Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 210000003737 chromaffin cell Anatomy 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 230000027984 hippocampus development Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000276 neural tube Anatomy 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 230000007472 neurodevelopment Effects 0.000 description 2
- 210000005044 neurofilament Anatomy 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000010243 pulse-chase analysis Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- 230000007596 spatial working memory Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 1
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005885 Blunted affect Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010028310 Calbindin 1 Proteins 0.000 description 1
- 102000016838 Calbindin 1 Human genes 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001076388 Fimbria Species 0.000 description 1
- 206010016759 Flat affect Diseases 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010019070 Hallucination, auditory Diseases 0.000 description 1
- 206010019075 Hallucination, visual Diseases 0.000 description 1
- 241001559542 Hippocampus hippocampus Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000289619 Macropodidae Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000004213 Neuropilin-2 Human genes 0.000 description 1
- 108090000770 Neuropilin-2 Proteins 0.000 description 1
- 238000010826 Nissl staining Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241001282736 Oriens Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 241000724822 Teia Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004009 axon guidance Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000005016 dendritic process Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000007976 developmental deficit Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000008918 emotional behaviour Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000008801 hippocampal function Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000003522 neurite outgrowth assay Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000001769 parahippocampal gyrus Anatomy 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001871 perforant pathway Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000002813 septal nuclei Anatomy 0.000 description 1
- 210000002186 septum of brain Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000439 stratum lucidum Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000016776 visual perception Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011905180 | 2011-12-13 | ||
| AU2011905180A AU2011905180A0 (en) | 2011-12-13 | Method of treatment | |
| PCT/AU2012/001530 WO2013086574A1 (en) | 2011-12-13 | 2012-12-13 | Method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140116103A true KR20140116103A (ko) | 2014-10-01 |
Family
ID=48611719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147019564A Withdrawn KR20140116103A (ko) | 2011-12-13 | 2012-12-13 | 치료 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20140348793A1 (OSRAM) |
| EP (1) | EP2791324B1 (OSRAM) |
| JP (1) | JP2015500297A (OSRAM) |
| KR (1) | KR20140116103A (OSRAM) |
| CN (1) | CN104540938A (OSRAM) |
| AU (1) | AU2012350357A1 (OSRAM) |
| CA (1) | CA2859213A1 (OSRAM) |
| IN (1) | IN2014DN05769A (OSRAM) |
| WO (1) | WO2013086574A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022006404A1 (en) * | 2020-07-02 | 2022-01-06 | The Johns Hopkins University | Fmri-hippocampus acoustic battery (fhab) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030003572A1 (en) * | 1999-03-05 | 2003-01-02 | David J. Anderson | Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression |
| ITNA20060017A1 (it) * | 2006-02-20 | 2007-08-21 | Aquino Riccardo D | Tecnica di prelievo e selezione di un una popolazione di cellule staminali di tipo embrionale da tessuti follicolari peridentari di uomo adulto. |
| EP2531594B1 (en) * | 2010-02-03 | 2016-11-16 | Samsung Life Public Welfare Foundation | Method for proliferating stem cells by activating c-met/hgf signaling and notch signaling |
| US9920371B2 (en) * | 2011-09-22 | 2018-03-20 | Medvet Sciences Pty. Ltd. | Screening method |
-
2012
- 2012-12-13 KR KR1020147019564A patent/KR20140116103A/ko not_active Withdrawn
- 2012-12-13 CA CA2859213A patent/CA2859213A1/en not_active Abandoned
- 2012-12-13 CN CN201280069662.3A patent/CN104540938A/zh active Pending
- 2012-12-13 WO PCT/AU2012/001530 patent/WO2013086574A1/en not_active Ceased
- 2012-12-13 JP JP2014546242A patent/JP2015500297A/ja active Pending
- 2012-12-13 EP EP12856927.4A patent/EP2791324B1/en not_active Not-in-force
- 2012-12-13 US US14/365,569 patent/US20140348793A1/en not_active Abandoned
- 2012-12-13 IN IN5769DEN2014 patent/IN2014DN05769A/en unknown
- 2012-12-13 AU AU2012350357A patent/AU2012350357A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2791324A1 (en) | 2014-10-22 |
| EP2791324A4 (en) | 2015-04-29 |
| EP2791324B1 (en) | 2017-05-10 |
| IN2014DN05769A (OSRAM) | 2015-04-10 |
| US20140348793A1 (en) | 2014-11-27 |
| CA2859213A1 (en) | 2013-06-20 |
| WO2013086574A1 (en) | 2013-06-20 |
| CN104540938A (zh) | 2015-04-22 |
| JP2015500297A (ja) | 2015-01-05 |
| AU2012350357A1 (en) | 2014-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tincer et al. | Neural stem/progenitor cells in Alzheimer’s disease | |
| Karayannis et al. | Cntnap4 differentially contributes to GABAergic and dopaminergic synaptic transmission | |
| Goodliffe et al. | Absence of prenatal forebrain defects in the Dp (16) 1Yey/+ mouse model of Down syndrome | |
| Li et al. | Neural stem cells rescue nervous Purkinje neurons by restoring molecular homeostasis of tissue plasminogen activator and downstream targets | |
| Salehi et al. | Using mouse models to explore genotype–phenotype relationship in Down syndrome | |
| Wei et al. | Affiliative behavior requires juvenile, but not adult neurogenesis | |
| Chen et al. | Human‐Derived Induced GABAergic Progenitor Cells Improve Cognitive Function in Mice and Inhibit Astrocyte Activation with Anti‐Inflammatory Exosomes | |
| Strell et al. | Neuronal transplantation for Alzheimer’s disease and prospects for generating exogenic neurons as a source of cells for implantation | |
| KR20140116103A (ko) | 치료 방법 | |
| Crittenden et al. | Mutations in CalDAG-GEFI lead to striatal signaling deficits and psychomotor symptoms in multiple species including human | |
| Lin | Kv1. 1 regulation of adult hippocampal neurogenesis | |
| Hu et al. | Selective magnetoelectric stimulation antagonizes GABAA receptors subunit in the left prelimbic cortex neurons to alleviate schizophrenia-like behaviors | |
| Santhosh | Brain Region Specific Neurovascular Signaling and Germinal Matrix Hemmorhage | |
| Han | Analysis of adult hippocampal neurogenesis in neurodegenerative disease | |
| Aloni | Thesis for the degree | |
| Dincheva | The role of neurotrophins and neurotrophin-like receptors in CNS disorders: Modeling CNS disease in rodents | |
| Lou | The Role of eIF4E/4E-BP2 Dependent Translation in Epileptic Seizure | |
| Candemir | Involvement of neuronal nitric oxide synthase (NOS-I) PDZ interactions in neuropsychiatric disorders | |
| Wang | The study of Sonic Hedgehog signaling pathway functions in modulating neurogenesis and animal behaviors | |
| Zhang et al. | Spatial learning and expression of neural cell adhesion molecule L1 in rats X-irradiated prenatally | |
| Aloni | Ca2+ Stores in Animal Models of Alzheimer's Disease | |
| Abdi | Identifying Novel Targets to Restore Defects in Neurogenesis in the 3xTG Mouse Model of Alzheimer's Disease | |
| Steinzeig | Antidepressant-induced plasticity in the adult mouse visual cortex | |
| Grow | Neural cell fate in the context of improving translational medicine | |
| Olusakin | Serotonin and emotional behaviours: developmental role of the 5-HT7 receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20140714 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |